Table 2 Patients’ walking ability over 12 months of study period (FAS)
Walking ability, n (%) | Fingolimod cohort NÂ =Â 172 | Other DMTs cohort NÂ =Â 75 | ||||
|---|---|---|---|---|---|---|
Baseline n = 172 | Month 6 n = 134 | Month 12/EOS n = 111 | Baseline n = 75 | Month 6 n = 63 | Month 12/EOS n = 57 | |
Patients with walking ability assessment | 165 (95.9) | 112 (83.6) | 111 (100.0) | 75 (100.0) | 59 (93.7) | 57 (100.0) |
Walking ability assessment | ||||||
Unable to walk | 7 (4.2) | 1 (0.9) | 2 (1.8) | 6 (8.0) | 4 (6.8) | 1 (1.8) |
Not able to walk unrestricted outside home (assistive device used) | 16 (9.7) | 16 (14.3) | 15 (13.5) | 0 (0.0) | 3 (5.1) | 4 (7.0) |
Not able to walk unrestricted outside home (assistive device not used) | 21 (12.7) | 15 (13.4) | 10 (9.0) | 3 (4.0) | 1 (1.7) | 4 (7.0) |
Able to walk unrestricted outside home | 121 (73.3) | 80 (71.4) | 84 (75.7) | 66 (88.0) | 51 (86.4) | 48 (84.2) |